{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:35:29Z","timestamp":1753889729783,"version":"3.40.1"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,3,18]]},"DOI":"10.1001\/jama.2025.0088","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T16:01:01Z","timestamp":1740067261000},"page":"948","source":"Crossref","is-referenced-by-count":1,"title":["Can We Omit Surgery for Low-Risk Ductal Carcinoma In Situ of the Breast?"],"prefix":"10.1001","volume":"333","author":[{"given":"Seema A.","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Whelan","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University and Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"10445","key":"jed250001r1","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1016\/S0140-6736(24)00425-2","article-title":"Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.","volume":"403","author":"Delaloge","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"jed250001r3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv372","article-title":"Outcomes of active surveillance for ductal carcinoma in situ: a computational risk analysis.","volume":"108","author":"Ryser","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"jed250001r4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.26698","article-title":"Active monitoring with or without endocrine therapy for low-risk ductal carcinoma in situ: the COMET randomized clinical trial.","author":"Hwang","year":"2024","journal-title":"JAMA"},{"key":"jed250001r5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.6556","article-title":"Patient-reported outcomes for low-risk ductal carcinoma in situ: a secondary analysis of the COMET randomized clinical trial.","author":"Partridge","year":"2024","journal-title":"JAMA Oncol"},{"key":"jed250001r6","doi-asserted-by":"publisher","first-page":"m2215","DOI":"10.1136\/bmj.m2215","article-title":"Non-adherence in non-inferiority trials: pitfalls and recommendations.","volume":"370","author":"Mo","year":"2020","journal-title":"BMJ"},{"issue":"12","key":"jed250001r7","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/sim.10067","article-title":"Assessing efficacy in non-inferiority trials with non-adherence to interventions: are intention-to-treat and per-protocol analyses fit for purpose?","volume":"43","author":"Dodd","year":"2024","journal-title":"Stat Med"},{"issue":"10","key":"jed250001r8","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1245\/s10434-017-5927-y","article-title":"A validated nomogram to predict upstaging of ductal carcinoma in situ to invasive disease.","volume":"24","author":"Jakub","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"jed250001r9","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1245\/s10434-020-08576-6","article-title":"Do eligibility criteria for ductal carcinoma in situ (DCIS) active surveillance trials identify patients at low risk for upgrade to invasive carcinoma?","volume":"27","author":"Oseni","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"jed250001r10","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/jnci\/djy220","article-title":"Cancer outcomes in DCIS patients without locoregional treatment.","volume":"111","author":"Ryser","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"33","key":"jed250001r11","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1200\/JCO.2015.60.8588","article-title":"Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study.","volume":"33","author":"Solin","year":"2015","journal-title":"J Clin Oncol"},{"issue":"32","key":"jed250001r12","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1200\/JCO.21.01083","article-title":"Randomized phase III trial evaluating radiation following surgical excision for good-risk ductal carcinoma in situ: long-term report from NRG Oncology\/RTOG 9804.","volume":"39","author":"McCormick","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"jed250001r13","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/cncr.25635","article-title":"Expectant management versus immediate treatment for low-grade cervical intraepithelial neoplasia: a randomized trial in Canada and Brazil.","volume":"117","author":"Elit","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"jed250001r14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10549-020-06042-1","article-title":"Treating (low-risk) DCIS patients: what can we learn from real-world cancer registry evidence?","volume":"187","author":"Byng","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"jed250001r15","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1245\/s10434-015-4668-z","article-title":"Adjuvant endocrine therapy in patients with ductal carcinoma in situ: a population-based retrospective analysis from 2005 to 2012 in the National Cancer Data Base.","volume":"22","author":"Flanagan","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"jed250001r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113276","article-title":"Active surveillance versus treatment in low-risk DCIS: women\u2019s preferences in the LORD trial.","volume":"192","author":"Schmitz","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"jed250001r17","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1186\/s13063-023-07703-4","article-title":"Recruiting women with ductal carcinoma in situ to a randomised controlled trial: lessons from the LORIS study.","volume":"24","author":"Wheelwright","year":"2023","journal-title":"Trials"},{"issue":"8","key":"jed250001r18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/jjco\/hyx059","article-title":"Current approach and future perspective for ductal carcinoma in situ of the breast.","volume":"47","author":"Kanbayashi","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"jed250001r2","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer. Updated March 23, 2023. Accessed April 30, 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2830686\/jama_khan_2025_ed_250001_1741284961.54046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T15:02:25Z","timestamp":1742310145000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2830686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,3,18]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.0088","relation":{},"ISSN":["0098-7484"],"issn-type":[{"type":"print","value":"0098-7484"}],"subject":[],"published":{"date-parts":[[2025,3,18]]}}}